search query: @indexterm Pharmaceutical industry / total: 673
references: 21-30 / 673
« previous page | next page »
 titleyearauthor
21.
Countervailing power in wholesale pharmaceuticals
Journal of Industrial Economics
2010 : MAR, VOL. 58:1, p. 32-53
 2010 Ellison, S.F.
Snyder, C.M.
22.
Benchmarking and transparency: incentives for the pharmaceutical industry’s corporate social responsibility
Journal of Business Ethics
2010 : SEP, VOL. 95:4, p. 641-658
 2010 Lee, M.
Kohler, J.
23.
Leveraging internal and external experience: exploration, exploitation, and R&D project performance
Strategic Management Journal
2010 : JUL, VOL. 31:7, p. 734-758
 2010 Hoang, H.
Rothaermel, F.T.
24.
Ideas at work: sparkling innovation
Business Strategy Review
2010 : SUMMER, JUN, VOL. 21:2, p. 7-11
 2010 Birkinshaw, J.
Robbins, P.
25.
Garbage-can decision making and the accommodation of uncertainty in new drug development work
Creativity and innovation management
2010 : JUN, VOL. 19:2, p. 134-146
 2010 Styhre, A. (et al.)
26.
From recipe to dinner: Business model portfolios in the European biopharmaceutical industry
Long Range Planning
2010 : APR/JUN, VOL. 43:2-3, p. 431-447
 2010 Sabatier, V.
Mangematin, V.
Rousselle, T.
27.
Managing technological transitions through R&D alliances
R & D Management
2009 : MAR, VOL. 39:2, p. 124-135
 2009 Riccaboni, M.
Moliterni, R.
28.
Implementing Lean Sigma in pharmaceutical research and development: a review by practitioners
R & D Management
2009 : JAN, VOL. 39:1, p. 95-106
 2009 Carleysmith, S.W.
Dufton, A.M.
Altria, K.D.
29.
Exploring the internal and external venturing of large R&D-intensive firms
R & D Management
2009 : JUN, VOL. 39:3, p. 231-246
 2009 Williams, C.
Lee, S.H.
30.
Innovation and the welfare effects of public drug insurance
Journal of Public Economics
2009 : APR, VOL. 93:3-4, p. 541-548
 2009 Lakdawalla, D.
Sood, N.
« previous page | next page »
SCIMA